Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 9Fallopian Tube Neoplasms 8Neoplasms 6Prostatic Neoplasms 5Carcinoma, Ovarian Epithelial 5Recurrence 3Pancreatic Neoplasms 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Metastatic Castration Resistant Prostate Cancer 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Sarcoma 1Primary Myelofibrosis 1Pathologic Complete Response 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1

Interventions

Carboplatin 3Pemetrexed 2Paclitaxel 2Gemcitabine 2rucaparib 1relacorilant 1niraparib 1nintedanib 1liposomal doxorubicin 1atezolizumab 1Watchful Waiting 1Transurethral Resection of Prostate 1Pregnancy Tests 1Ocoxin 1Nivolumab 1Human Papillomavirus DNA Tests 1Fulvestrant 1E-3810 1Drug Therapy 1Darbepoetin alfa 1Colposcopy 1Cell Count 1Biopsy 1Bevacizumab 1Acetic Acid 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Genital Neoplasms, Female × rucaparib × Clear all
NCT03101280 2020-10-22

A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer

Hoffmann-La Roche

Phase 1 Completed
29 enrolled

Genital Neoplasms, Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡